Abstract: A pigment with a metallic luster, comprising a wafer-like substrate made of aluminium dioxide having a thickness of more than 250 nm and less than 1 ?m, which is fully enveloped by a metal layer.

Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of negative dielectric anisotropy which comprises at least one compound of the formula I in which R11 and R12, ring A, Z, a, L1 and L2 are as defined in claim 1, and the use thereof for an active-matrix display based on the ECB effect.

Abstract: Novel compounds of the formula I in which D, M, W, X, Y, T and R1 are as defined in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.

Abstract: Amide and urea derivatives of the formula I R1—(CH2)n—(Y)q-(Z)r-CO—NH—R2 ??(I) in which R1, n, Y, q, Z, r and R2 have the meanings indicated in claim 1, are potent 5-HT1B/1D antagonists and exhibit 5-HT reuptake-inhibiting actions and are suitable for the treatment and prophylaxis of anxiety states, depressions, schizophrenia, compulsive ideas, tardive dyskinesias, learning disorders, age-dependent memory disorders, for positively affecting obsessive-compulsive behaviour (OCD), and also for the treatment and for the control of the sequelae of cerebral infarcts such as stroke and cerebral ischaemias.

Abstract: Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

Abstract: A birefringent film comprising at least one birefringent layer of liquid crystal material forming multi domains with a splayed structure may be coated onto a reflective substrate, e.g., with an aluminium surface. The birefringent film is particularly suited for decorative, security, authentification or identification applications.

Abstract: Lipid Binding Protein 4 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Lipid Binding Protein 4 polypeptides and polynucleotides in diagnostic assays.

Abstract: The present invention relates to the colored inscription or marking of plastics and surface coatings, including powder coatings, in which a colorant is transferred into the plastic or surface coating by laser radiation with the aid of a laser light-absorbent substance.

Abstract: The invention relates to the use of salt-based compounds as additives in electrolytes for improvinq the properties of electrochemical cells.

Abstract: The invention generally relates to a method of formylating organic compounds in a microreactor.

Abstract: A microcomponent connection system (1) having an accomodation device for plate-shaped microcomponents (7) has a connection block (2) and a lifting device (6), by means of which the microcomponent (7) and the connection block (2) can be pressed against one another. The connection block (2) has electrical and fluid line connections (8, 9) and optical line connections (16), each of which projects in a sprung or spring-mounted manner on the underside of the connection block (2). In order to connect the microcomponent (7) to the associated line connections (8, 9, 16), the microcomponent (7) is pressed by the lifting device (6) in the direction of the connection block (2) against the electrical line connections (8) or fluid line connections (9) designed as electrically conducting spring tongues or as hollow rams (10), or optical line connections (16).

Abstract: Aqueous coating solution having a pH of from 3 to 8, comprising 0.5-5.0% by weight of [SiOx(OH)y]n particles, where 0<y<4 and 0<x<2, having a particle size of from 10 nm to 60 nm with a tolerance of ±10%, and from 0.005 to 0.5% by weight, based on the coating solution, of a surfactant mixture obtainable by hydrolytic polycondensation of tetraalkoxysilanes in an aqueous-alcoholic-ammoniacal medium at temperatures between 35° C. and 80° C., with subsequent removal of ammonia and alcohol from the resultant dispersion by steam distillation and subsequent addition of a surfactant mixture comprising 15-30% by weight of anionic surfactants, 5-15% by weight of nonionic surfactants and less than 5% by weight of amphoteric surfactants.

Abstract: The invention relates to a process for the preparation of cyclic carboxylic acid orthoester fluorides in which a) at least one bis(alkylthio)carbenium salt is reacted with at least one organic compound containing at least two hydroxyl groups in the presence of at least one base, b) and subsequently, preferably in situ, the resultant thioorthoester is subjected to oxidative fluorodesulfurisation using a fluorinating agent and an oxidant to give the cyclic carboxylic acid orthoester fluoride.

Abstract: The invention relates to 2,4?-substituted 6-cyclohexyl-trans-decalins of the general formula I in which R1, R2 and Z are as defined in Claim 1, to the use thereof as components of liquid-crystalline media, and to a liquid-crystal display element and an electro-optical display element.

Abstract: The invention relates to new reactive mesogenic benzodithiophene derivatives, their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like for example liquid crystal displays, optical films, organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to a field effect transistor, light emitting device or ID tag comprising the reactive mesogenic benzodithiophenes.

Abstract: The invention relates to an optical compensator for liquid crystal displays comprising: at least one O plate retarder (3, 3?), and at least one twisted A plate retarder (6, 6?) with a twist angle ? of more than 90°, and further relates to a liquid crystal display comprising such a compensator, a liquid crystal cell (1) and polarizers (2, 2?).

Abstract: The invention relates to liquid-crystalline compounds of the formula I and to a liquid-crystalline medium based on a mixture of polar compounds, characterized in that it comprises one or more compounds of the general formula I in which R1, L1, L2, L3, L4, L5, L6, Z1, Z2, X, v and u are as defined in claim 1.

Abstract: The invention relates to a novel purified recombinant ?V?3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system. The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural ?v?3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the souluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes. The invention relates, furthermore, to a corresponding process for preparing recombinant full-length ?V?3 adhesion receptor in excellent yields, additionally using detergents to dissolve the membrane bound receptor from the surface of the host cell.

Abstract: Compounds of the formula (1), in which R1, R2?, R2?, R2??, R3 and n are as defined in claim 1, are effectors of the nicotinic and/or muscarinic acetylcholine receprot and are suitable for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds.

Abstract: A liquid-crystalline medium comprises one or more compounds of the general formula (I) CF3O-a-b-c-F??(I) in which a, b, c may each denote, independently of one another, and further liquid-crystalline compounds.